Tags

Type your tag names separated by a space and hit enter

18F-FDG PET diagnostic and prognostic patterns do not overlap in Alzheimer's disease (AD) patients at the mild cognitive impairment (MCI) stage.
Eur J Nucl Med Mol Imaging. 2017 Nov; 44(12):2073-2083.EJ

Abstract

PURPOSE

We aimed to identify the cortical regions where hypometabolism can predict the speed of conversion to dementia in mild cognitive impairment due to Alzheimer's disease (MCI-AD).

METHODS

We selected from the clinical database of our tertiary center memory clinic, eighty-two consecutive MCI-AD that underwent 18F-fluorodeoxyglucose (FDG) PET at baseline during the first diagnostic work-up and were followed up at least until their clinical conversion to AD dementia. The whole group of MCI-AD was compared in SPM8 with a group of age-matched healthy controls (CTR) to verify the presence of AD diagnostic-pattern; then the correlation between conversion time and brain metabolism was assessed to identify the prognostic-pattern. Significance threshold was set at p < 0.05 False-Discovery-Rate (FDR) corrected at peak and at cluster level. Each MCI-AD was then compared with CTR by means of a SPM single-subject analysis and grouped according to presence of AD diagnostic-pattern and prognostic-pattern. Kaplan-Meier-analysis was used to evaluate if diagnostic- and/or prognostic-patterns can predict speed of conversion to dementia.

RESULTS

Diagnostic-pattern corresponded to typical posterior hypometabolism (BA 7, 18, 19, 30, 31 and 40) and did not correlate with time to conversion, which was instead correlated with metabolic levels in right middle and inferior temporal gyri as well as in the fusiform gyrus (prognostic-pattern, BA 20, 21 and 38). At Kaplan-Meier analysis, patients with hypometabolism in the prognostic pattern converted to AD-dementia significantly earlier than patients not showing significant hypometabolism in the right middle and inferior temporal cortex (9 versus 19 months; Log rank p < 0.02, Breslow test: p < 0.003, Tarone-Ware test: p < 0.007).

CONCLUSION

The present findings support the role of FDG PET as a robust progression biomarker even in a naturalist population of MCI-AD. However, not the AD-typical diagnostic-pattern in posterior regions but the middle and inferior temporal metabolism captures speed of conversion to dementia in MCI-AD since baseline. The highlighted prognostic pattern is a further, independent source of heterogeneity in MCI-AD and affects a primary-endpoint on interventional clinical trials (time of conversion to dementia).

Authors+Show Affiliations

Nuclear Medicine Unit, IRCCS AOU San Martino, IST and Department of Health Sciences, University of Genoa, Largo R. Benzi 10, 16132, Genoa, Italy. silviadaniela.morbelli@hsanmartino.it.Nuclear Medicine Unit, IRCCS AOU San Martino, IST and Department of Health Sciences, University of Genoa, Largo R. Benzi 10, 16132, Genoa, Italy.Clinical Neurology, Department of Neuroscience (DINOGMI), University of Genoa and IRCCS AOU San Martino-IST, Genoa, Italy.Clinical Neurology, Department of Neuroscience (DINOGMI), University of Genoa and IRCCS AOU San Martino-IST, Genoa, Italy.Clinical Neurology, Department of Neuroscience (DINOGMI), University of Genoa and IRCCS AOU San Martino-IST, Genoa, Italy.Clinical Neurology, Department of Neuroscience (DINOGMI), University of Genoa and IRCCS AOU San Martino-IST, Genoa, Italy.Nuclear Medicine Unit, IRCCS AOU San Martino, IST and Department of Health Sciences, University of Genoa, Largo R. Benzi 10, 16132, Genoa, Italy.Institute of Cognitive Sciences and Technologies, CNR, Rome, Italy. Department of Nuclear Medicine, Karolinska Hospital, Stockholm, Sweden.Clinical Neurology, Department of Neuroscience (DINOGMI), University of Genoa and IRCCS AOU San Martino-IST, Genoa, Italy.Nuclear Medicine Unit, IRCCS AOU San Martino, IST and Department of Health Sciences, University of Genoa, Largo R. Benzi 10, 16132, Genoa, Italy.Istituto Nazionale di Fisica Nucleare, Sezione di Genova, Genoa, Italy.Institute of Bioimaging and Molecular Physiology, National Research Council, Genoa, Italy.Nuclear Medicine Unit, IRCCS AOU San Martino, IST and Department of Health Sciences, University of Genoa, Largo R. Benzi 10, 16132, Genoa, Italy.Clinical Neurology, Department of Neuroscience (DINOGMI), University of Genoa and IRCCS AOU San Martino-IST, Genoa, Italy.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

28785843

Citation

Morbelli, Silvia, et al. "18F-FDG PET Diagnostic and Prognostic Patterns Do Not Overlap in Alzheimer's Disease (AD) Patients at the Mild Cognitive Impairment (MCI) Stage." European Journal of Nuclear Medicine and Molecular Imaging, vol. 44, no. 12, 2017, pp. 2073-2083.
Morbelli S, Bauckneht M, Arnaldi D, et al. 18F-FDG PET diagnostic and prognostic patterns do not overlap in Alzheimer's disease (AD) patients at the mild cognitive impairment (MCI) stage. Eur J Nucl Med Mol Imaging. 2017;44(12):2073-2083.
Morbelli, S., Bauckneht, M., Arnaldi, D., Picco, A., Pardini, M., Brugnolo, A., Buschiazzo, A., Pagani, M., Girtler, N., Nieri, A., Chincarini, A., De Carli, F., Sambuceti, G., & Nobili, F. (2017). 18F-FDG PET diagnostic and prognostic patterns do not overlap in Alzheimer's disease (AD) patients at the mild cognitive impairment (MCI) stage. European Journal of Nuclear Medicine and Molecular Imaging, 44(12), 2073-2083. https://doi.org/10.1007/s00259-017-3790-5
Morbelli S, et al. 18F-FDG PET Diagnostic and Prognostic Patterns Do Not Overlap in Alzheimer's Disease (AD) Patients at the Mild Cognitive Impairment (MCI) Stage. Eur J Nucl Med Mol Imaging. 2017;44(12):2073-2083. PubMed PMID: 28785843.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - 18F-FDG PET diagnostic and prognostic patterns do not overlap in Alzheimer's disease (AD) patients at the mild cognitive impairment (MCI) stage. AU - Morbelli,Silvia, AU - Bauckneht,Matteo, AU - Arnaldi,Dario, AU - Picco,Agnese, AU - Pardini,Matteo, AU - Brugnolo,Andrea, AU - Buschiazzo,Ambra, AU - Pagani,Marco, AU - Girtler,Nicola, AU - Nieri,Alberto, AU - Chincarini,Andrea, AU - De Carli,Fabrizio, AU - Sambuceti,Gianmario, AU - Nobili,Flavio, Y1 - 2017/08/07/ PY - 2017/04/27/received PY - 2017/07/23/accepted PY - 2017/8/9/pubmed PY - 2018/5/31/medline PY - 2017/8/9/entrez KW - 18F–FDG PET KW - AD-biomarkers KW - Alzheimer’s disease KW - Mild cognitive impairment SP - 2073 EP - 2083 JF - European journal of nuclear medicine and molecular imaging JO - Eur J Nucl Med Mol Imaging VL - 44 IS - 12 N2 - PURPOSE: We aimed to identify the cortical regions where hypometabolism can predict the speed of conversion to dementia in mild cognitive impairment due to Alzheimer's disease (MCI-AD). METHODS: We selected from the clinical database of our tertiary center memory clinic, eighty-two consecutive MCI-AD that underwent 18F-fluorodeoxyglucose (FDG) PET at baseline during the first diagnostic work-up and were followed up at least until their clinical conversion to AD dementia. The whole group of MCI-AD was compared in SPM8 with a group of age-matched healthy controls (CTR) to verify the presence of AD diagnostic-pattern; then the correlation between conversion time and brain metabolism was assessed to identify the prognostic-pattern. Significance threshold was set at p < 0.05 False-Discovery-Rate (FDR) corrected at peak and at cluster level. Each MCI-AD was then compared with CTR by means of a SPM single-subject analysis and grouped according to presence of AD diagnostic-pattern and prognostic-pattern. Kaplan-Meier-analysis was used to evaluate if diagnostic- and/or prognostic-patterns can predict speed of conversion to dementia. RESULTS: Diagnostic-pattern corresponded to typical posterior hypometabolism (BA 7, 18, 19, 30, 31 and 40) and did not correlate with time to conversion, which was instead correlated with metabolic levels in right middle and inferior temporal gyri as well as in the fusiform gyrus (prognostic-pattern, BA 20, 21 and 38). At Kaplan-Meier analysis, patients with hypometabolism in the prognostic pattern converted to AD-dementia significantly earlier than patients not showing significant hypometabolism in the right middle and inferior temporal cortex (9 versus 19 months; Log rank p < 0.02, Breslow test: p < 0.003, Tarone-Ware test: p < 0.007). CONCLUSION: The present findings support the role of FDG PET as a robust progression biomarker even in a naturalist population of MCI-AD. However, not the AD-typical diagnostic-pattern in posterior regions but the middle and inferior temporal metabolism captures speed of conversion to dementia in MCI-AD since baseline. The highlighted prognostic pattern is a further, independent source of heterogeneity in MCI-AD and affects a primary-endpoint on interventional clinical trials (time of conversion to dementia). SN - 1619-7089 UR - https://www.unboundmedicine.com/medline/citation/28785843/18F_FDG_PET_diagnostic_and_prognostic_patterns_do_not_overlap_in_Alzheimer's_disease__AD__patients_at_the_mild_cognitive_impairment__MCI__stage_ L2 - https://dx.doi.org/10.1007/s00259-017-3790-5 DB - PRIME DP - Unbound Medicine ER -